NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. Earnings Recaps

NRXP Health Care 1 recap
Next earnings: November 13, 2026 (estimated) · full calendar
Q2 2026 Aug 19, 2026

NRx Pharmaceuticals shares rose 5.2% following Q2 results, driven by significant progress toward regulatory approvals and a promising federally backed clinical trial partnership that expands the potential market for NRX-101.

Key takeaways
  • Completed first FDA review cycle for preservative-free ketamine ANDA with only one minor manufacturing-related deficiency remaining, targeting approval in 2026.
  • Advanced NRX-100 NDA with strong external alignment, supported by White House and Congressional guidance endorsing real-world evidence for psychedelic depression treatments; aiming for 2027 approval.
  • Secured a prime contractor role with DARPA for the SPARC-TMS trial of NRX-101 combined with robotic TMS, potentially opening a large new market in military and first responder mental health.
  • Expanded HOPE Therapeutics clinical footprint in Florida, supporting growth ambitions.
  • Ordered 5 million units of launch stock for preservative-free ketamine, reflecting confidence in upcoming commercial readiness.
Full recap

Go deeper on NRXP and the wider market.

All earnings recaps Browse the latest results across the market. Stock directory Browse companies by sector and market. Highest-yield stocks A curated screen of top dividend payers. Investing glossary Plain-English definitions for every metric.